The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice.
 
Estelamari Rodriguez
Consulting or Advisory Role - AstraZeneca; Oncocyte; Research to Practice
Speakers' Bureau - Genentech
 
Richa Dawar
Honoraria - Agendia; Bayer; Targeted Oncology
Consulting or Advisory Role - Agendia; Daiichi Sankyo; Onc Live; Targeted Oncology
 
Fahmin Basher
No Relationships to Disclose
 
Philippos Apolinario Costa
No Relationships to Disclose
 
Tisdrey Torres
No Relationships to Disclose
 
Dao M. Nguyen
No Relationships to Disclose
 
Nestor Villamizar
No Relationships to Disclose
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer